Compare Quanta Services Inc (PWR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Zoetis Inc — how do they compare? Quanta Services Inc trades at $705.05 (market cap $103.03B), while Zoetis Inc trades at $74.55 (market cap $30.20B). The key difference: Quanta Services Inc is far larger — about 3.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and Zoetis Inc for 70 Days on average.
| PWR | ZTS | |
|---|---|---|
Market Cap | $103.03B | $30.20B |
Volume | 977,892 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $785.24 | $147.53 |
52-Week Low | $412.21 | $69.09 |
Typical Hold Time | 62 Days | 70 Days |
Enterprise Value | $109.13B | $37.76B |
Dividend Yield | 0.06% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $701.01, down slightly by 0.01% on the day, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. A record backlog of $53B and positive news on AI infrastructure demand highlight near-term catalysts.
Outlook is positive given earnings momentum and sector tailwinds, but high valuation ratios (P/E of 78.41) and execution risks on large projects pose challenges. With 75% of analysts rating it a Buy and a consensus price target of $802.08, upside potential exists if growth sustains.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
